pH-impedance testing detects refl ux events irrespective of pH, but its value in predicting treatment outcome is unclear. We prospectively evaluated subjects treated medically after pH-impedance testing to determine predictors of symptom improvement.
INTRODUCTION
Combined esophageal multichannel intra-luminal impedance and pH monitoring represents a relatively new technology in which serial impedance sensors on a catheter detect changes in resistance (impedance) to electrical current and, consequently, the presence of content or bolus within the esophageal lumen to complement pH monitoring ( 1 ) . Th is arrangement determines the direction of esophageal bolus movement (anterograde , as in swallowed bolus, or retrograde, as in refl ux), quantifi cation of bolus pH via accompanying pH electrodes, and evaluation of symptom association with refl ux episodes ( 2 ) . As pH-impedance testing detects refl ux irrespective of pH, monitoring can be performed in subjects undergoing anti-secretory therapy ( 3 ) .
In the past decade, studies, consensus reports, and practice guidelines have all suggested that pH-impedance monitoring detects refl ux episodes with higher diagnostic sensitivity compared Acid-Based Parameters on pH-Impedance Testing Predict Symptom Improvement With Medical Management Better Than Impedance Parameters with traditional pH testing alone ( 4 -8 ) . Further, multicenter studies have shown an increased diagnostic yield for detection of non-acidrefl ux events when pH-impedance testing is performed on antisecretory therapy ( 9 -10 ) . Specifi cally, symptom -refl ux association techniques such as the symptom index (SI) and symptom association probability (SAP) have been used to evaluate the temporal relationships between symptoms and detected refl ux events ( 11, 12 ) .
However, debate continues as to whether the clinical utility of pH-impedance testing in predicting symptomatic outcome is greater when performed on or off anti-secretory therapy ( 13 -15 ) . Th is discourse stems partly from the yet unclear clinical significance of non-acid-refl ux events on anti-secretory therapy. Nonacid-refl ux events are indeed much fewer aft er anti-refl ux surgery (ARS) compared with healthy volunteers ( 16 ) , and limited data suggest that the presence of symptom -refl ux association with nonacid events may predict response to ARS ( 17 -19 ) . However, available literature does not provide concordant guidance on whether testing on or testing off anti-secretory therapy provides better predictive utility, especially for continuing medical management in contrast to ARS.
Th erefore, although pH-impedance testing may increase the yield of detecting refl ux events and may assist with the selection of patients for ARS, it remains unclear whether or how impedance parameters add value to the predictive power of long-established acid-based parameters. For the purposes of this report, we hypothesized that, as gastroesophageal refl ux disease (GERD) is indeed an acid-mediated disease, acid parameters should drive medical management with anti-secretory therapy. We sought to determine whether impedance parameters contribute adjunctive benefi ts to predicting symptomatic outcomes in the medical management of GERD and, if so, which impedance parameters have the best clinical utility in this regard.
METHODS

Subjects
All adult patients ( ≥ 18 years) with persistent GERD symptoms despite seemingly adequate anti-secretory therapy referred to the Gastroenterology Motility Center at Washington University in Saint Louis, Missouri, between January 2005 and August 2010 for ambulatory pH-impedance testing were eligible for inclusion. Patients with histopathology-based esophageal motility disorders (e.g., achalasia, scleroderma esophagus), past history of esophageal surgery including fundoplication, and patients with inadequate (defi ned as poor data quality with signifi cant artifact precluding data analysis) or incomplete (defi ned as recording time < 14 h) studies were excluded. Consent was obtained from each patient for review of their clinical data and for answering survey questions pertaining to this study. Th is study protocol was approved by the Human Research Protection Offi ce (Institutional Review Board) at Washington University in Saint Louis.
Data collection
Before pH-impedance testing, all patients completed a subjective symptom survey to characterize their dominant and secondary symptoms as well as their overall symptomatic status. In this symptom survey, symptom frequency and severity are individually rated on fi ve-point Likert scales generated a priori for esophageal physiologic tests at our institution; these scales have been used in similar published outcome assessments ( 20, 21 ) . Th e scale of symptom frequency ranges from 0 (for no symptoms) to 4 (for multiple daily episodes). Similarly, the scale of symptom severity ranges from 0 (for no symptoms) to 4 (for very severe symptoms). Symptom intensity may then be calculated as the product of symptom frequency and symptom severity, with a maximum possible score of 16. In addition, overall global symptom severity (GSS) is recorded on a 100-point visual analog scale.
At our institution, pH-impedance testing is designated as " open access " . Th erefore, pH and pH-impedance studies are requested by referring gastroenterologists or surgeons not only for the purposes of quantifi cating acid exposure and affi rming the presence of refl ux disease but also for ruling out refl ux disease in certain instances; the referring physicians determine whether testing should be performed on or off anti-secretory therapy. To refl ect this fact and to address a ' ' real-world ' ' practice pattern, we included both sets of patients, those tested on and those off anti-secretory therapy, in this study. When pH-impedance testing is performed off antisecretory therapy, patients are required to discontinue anti-secretory therapy at least 7 days prior to the study, and histamine-2 receptor antagonists, prokinetic agents, and antacids at least 3 days prior to the study. All pH-impedance studies are performed aft er an overnight fast. Th e pH-impedance catheter (Sandhill Scientifi c, Highlands Ranch, CO), with six impedance electrodes and one pH sensor, is inserted transnasally with the esophageal pH sensor positioned 5 cm proximal to the manometrically localized lower esophageal sphincter. Th is catheter confi guration allows for monitoring changes in intra-luminal impedance at 3, 5, 7, 9, 15, and 17 cm above the lower esophageal sphincter.
Aft er catheter placement, patients are then instructed to resume their normal daily activities and diet. Each patient is provided a diary to record the timing of meals, activities, and symptoms. Moreover, patients are instructed to press buttons on an electronic recording device corresponding to symptom events. Approximately 24 h aft er catheter placement, patients return to the Motility Center for catheter removal. Data are then uploaded into and analyzed with dedicated soft ware (Bioview Analysis; Sandhill Scientifi c). Th is soft ware was used to collect and calculate the number of refl ux events, exposure times, and symptom -refl ux correlation parameters. Automated analysis was used to initially interrogate the pH-impedance studies. Studies were independently evaluated by two investigators (A.P. and C.P.G.), and discordance was resolved by discussion.
Parameters derived from raw pH-impedance data included the acid-exposure time (AET) and the refl ux-exposure time (RET). Th e AET provided a quantitative measure of the time for which esophageal pH remained below 4 in the distal esophagus, expressed as a percentage. A total AET of ≥ 4.0 % was considered abnormal for the purposes of this study, per our institutional threshold with documented sensitivity (91 % ) and specifi city (85 % ) for discriminating esophagitis ( 22 ) . Th e RET was used as a surrogate quantitative measure of refl ux, and was defi ned as the percentage of time for which refl uxate was in contact with the pair of distal esophageal impedance electrodes located adjacent to the esophageal pH sensor 5 cm above the lower esophageal sphincter. For a refl ux event to be captured and included in the calculation of the RET, the refl uxate needed to be detected in three consecutive distal pairs of impedance electrodes. Th e RET was then calculated as an aggregate of the amount of time that refl uxate remained in contact with the distal impedance electrode, and was reported as a percentage over 24 h. For the purposes of this study, the RET was considered elevated if the value was ≥ 1.4 % , a threshold which has been validated ( 23 ) .
For symptom -refl ux correlation, only symptoms that occurred within 2 min of a pH-or impedance-detected refl ux event were considered. SAP was calculated using the Ghillebert probability estimate as the sum of partial probabilities for the exact numbers of refl ux-associated symptoms within the context of the total number of symptoms, taking the total duration of the pH-impedance study and the total exposure time into consideration ( 24, 25 ) . Th e SAP was considered positive if the likelihood of a chance association between the refl ux event and the symptom was < 5 % (i.e., P < 0.05). Th e SI was calculated as the ratio of refl ux-related symptoms to the total number of recorded symptoms, and was considered positive if ≥ 50 % ( 26 ) . Th e SI and SAP were each calculated fi rst with pHdetected acid-refl ux events, then recalculated with all impedancedetected refl ux events.
Patients with complete demographic, pH-impedance, and symptom data were subsequently prospectively contacted to assess treatment approaches and symptom outcomes. Treatment approaches were implemented by each patient ' s treating gastroenterologist or surgeon, taking into account the pH-impedance test results, conventional clinical algorithms, and each patient ' s individual health and personal preferences; these decisions were not infl uenced or altered by this study. Symptomatic outcomes were assessed by re-administering the pre-procedure symptom survey. Th e overall symptomatic outcome was quantifi ed as changes in GSS and symptom intensity scores. Subjects tested on and off proton pump inhibitor (PPI) therapy were analyzed separately and results were compared.
Data analysis
Data are reported as the mean ± standard error of the mean (s.e.m.) unless stated otherwise. Categorical data were compared using the χ 2 -test or Fisher ' s exact test as appropriate. Grouped data were compared using the two-tailed Student ' s t -test. Univariate and multivariate analyses were performed to identify fi ndings that predicted an improved symptomatic outcome, measured as both linear GSS change and ≥ 50 % GSS improvement upon follow-up. Linear regression models were created to determine predictors of a successful symptomatic outcome with medical management, controlling for the use of anti-secretory therapy during testing, and included clinical demographic data as well as all traditional acid and impedance parameters as variables since these parameters tend to be linked as covariates. In all cases, P < 0.05 was required for statistical signifi cance. All statistical analyses were performed using IBM SPSS Statistics V.21.0 (Armonk, NY).
RESULTS
Interrogation of the pH-impedance database revealed 302 patients who underwent ambulatory pH-impedance testing for GERD symptoms during the 5-year study period. A total of 60 patients did not meet inclusion criteria (7 had inadequate or incomplete studies, 3 had histopathology-based esophageal motility disorders, 26 had prior fundoplication or other esophageal surgery, and 24 were missing pre-procedure symptom surveys), 59 patients were managed surgically, 53 could not be contacted for follow-up, and 2 declined to participate; these subjects were excluded. Th e remaining 128 subjects (53.3 ± 1.3 years, 66.4 % female, 82.8 % Caucasian) underwent medical therapy for refl ux symptoms, fulfi lled study inclusion criteria, were successfully contacted by telephone, consented to participate in the study, and constituted the study sample.
Typical refl ux symptoms were reported by 73 (57.0 % ) patients (38 with heartburn, 35 with regurgitation), whereas the remaining 55 (43.0 % ) presented with atypical symptoms (15 with chest pain, 37 with cough, 2 with hoarseness, 1 with throat clearing). Testing was performed off anti-secretory therapy in 46.1 % patients and on therapy in 53.9 % ; these two groups were each analyzed separately below and represented our two primary groups for comparison. Th ere were no diff erences in demographic or clinical parameters, baseline symptom intensity, or baseline GSS between these two subsets ( P ≥ 0.136 for each comparison, Table 1 ).
Collectively, 21.9 % of patients had an abnormal AET and 45.3 % had an abnormal RET ( Table 2 ). Reported symptoms and number of acid-refl ux events were signifi cantly higher when testing was performed off anti-secretory therapy ( Figure 1 ). Number of refl ux events detected by impedance was signifi cantly higher than that detected by pH monitoring, as expected. Consequently, symptom -refl ux association was proportionately higher with impedance-detected refl ux events compared with acid-detected refl ux events (SI: 31.3 vs. 11.7 % , respectively, P < 0.001; SAP: 38.3 vs. 21.1 % , respectively, P = 0.003; Figure 1 ). A signifi cantly higher proportion demonstrated symptom -refl ux correlation (as assessed by Ghillebert probability estimate) in patients tested off PPI, with both acid-refl ex events ( P < 0.001) and all refl ux events detected by impedance ( P = 0.028). Proportions of patients with other acid and impedance parameters did not diff er between subjects tested on and those tested off anti-secretory therapy, with P ≥ 0.09 for each comparison ( Table 2 ). However, there were more subjects with abnormal AET in the cohort tested off PPI (28.8 % compared with 15.9 % on PPI, P = 0.09). Proportions with concordance between abnormal AET and acid-based refl ux -symptom association, and abnormal RET and impedance-based refl ux -symptom association also were similar in these two subsets.
At the end of 3.35 ± 0.14 years of follow-up, mean GSS collectively improved from a baseline of 60.4 ± 2.3 to 33.2 ± 2.3, a decline of 45.0 % . Dominant symptom intensity improved from 8.4 ± 0.5 to 4.3 ± 0.4, a decrease of 48.8 % . Overall, 54 (42.2 % ) subjects reported a GSS improvement of ≥ 50 % , and 74 (57.8 % ) subjects reported an improvement in dominant symptom intensity ≥ 50 % . Mean GSS improvement was not diff erent between cohorts tested on or off anti-secretory therapy ( P = 0.529); however, there was a trend toward higher rates of ≥ 50 % GSS improvement in subjects tested
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Acid Parameters on pH-Impedance Testing off anti-secretory therapy ( P = 0.066; Table 1 ). Mean GSS improvement tended to be better with atypical symptoms ( − 32.4 ± 4.4) compared with typical symptoms ( − 22.6 ± 3.7) with a nonsignificant trend ( P = 0.085); atypical symptom presentation was significantly associated with a higher rate of ≥ 50 % improvement in GSS ( P = 0.027; Table 3 ). GSS improvement was similar between patients with elevated AET detected off therapy and on therapy ( − 42.8 ± 9.1 vs. − 38.0 ± 8.4, respectively, P = 0.72); change in dominant symptom intensity was also similar ( − 5.8 ± 1.5 vs. − 4.7 ± 1.7, P = 0.66).
All patients
On univariate analysis, acid parameters were signifi cantly associated with linear GSS improvement. Both total AET as a continuous variable ( P = 0.026) and abnormal AET above 4.0 % ( P = 0.008) signifi cantly predicted GSS improvement in our study population. However, neither SI nor SAP calculated with acid-refl ux events predicted GSS improvement. Among impedance parameters, only SAP calculated with impedance-detected refl ux events signifi cantly predicted GSS improvement ( P = 0.008); RET above AET, acid exposure time; PPI: proton pump inhibitor; RET, refl ux exposure time; SAP, symptom association probability assessed by the Ghillebert probability estimate; SI, symptom index.
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tors of linear GSS change, only positive SAP for all refl ux events signifi cantly predicted GSS improvement ( P = 0.011), although other acid and impedance parameters did not ( P ≥ 0.11 for all). Moreover, only AET ≥ 4.0 % predicted ≥ 50 % GSS improvement on univariate analysis ( P = 0.049), whereas other acid and impedance parameters did not ( P ≥ 0.22 for all; Table 4 ). On multivariate analysis evaluating predictors of linear GSS improvement, only AET ≥ 4.0 % represented a signifi cant predictor ( P = 0.02), while impedance SAP trended toward signifi cance ( P = 0.06), but other clinical characteristics and testing parameters did not ( P ≥ 0.15 for all, Figure 2 ). Also, on multivariate analysis, only AET ≥ 4.0 % signifi cantly predicted ≥ 50 % GSS improvement ( P = 0.02), whereas atypical symptom presentation again trended toward signifi cance ( P = 0.07), and other parameters did not reach signifi cance ( P ≥ 0.16 for all).
Testing off PPI
Similarly, the 59 subjects who underwent testing off anti-secretory therapy were analyzed separately. On univariate analysis, only total AET signifi cantly predicted linear GSS improvement ( P = 0.04), while abnormal AET above 4.0 % strongly trended toward doing so ( P = 0.05), but other acid and impedance parameters did not reach signifi cance ( P ≥ 0.21 for all). Moreover, total AET ( P = 0.10) and AET ≥ 4.0 % ( P = 0.06) trended toward predicting ≥ 50 % GSS improvement on univariate analysis ( Table 4 ) .
On multivariate analysis of these subjects tested off anti-secretory therapy, only AET ≥ 4.0 % signifi cantly predicted linear GSS improvement ( P = 0.02), while established thresholds for total numbers of refl ux events trended toward signifi cance ( P = 0.05, Figure 2 ). Also on multivariate analysis, AET ≥ 4.0 % ( P = 0.02) and thresholds for total numbers of refl ux events ( P = 0.03) represented predictors of ≥ 50 % GSS improvement, although other parameters did not ( P ≥ 0.24 for all).
DISCUSSION
In this study, we demonstrate that acid-based refl ux para meters have higher clinical utility compared with commonly used 1.4 % , RET as a continuous variable, SI for all refl ux events, and thresholds for total number of refl ux events (either 73 or 48 refl ux events) did not. Univariate analysis assessing predictors of ≥ 50 % GSS improvement demonstrated total AET ( P = 0.028), AET ≥ 4.0 % ( P = 0.003), and SAP for all refl ux events ( P = 0.061) as signifi cant predictors ( Table 4 ) .
On multivariate analysis controlling for PPI status, only AET ≥ 4.0 % ( P = 0.003) and SAP calculated for all refl ux events ( P = 0.029) predicted linear GSS improvement, whereas age, gender, anti-secretory therapy, typical symptom presentation, RET ≥ 1.4 % , SAP calculated for acid-refl ux events, and established thresholds for total numbers of refl ux events (48 off therapy, 73 on therapy) did not ( P ≥ 0.17 for all). For ≥ 50 % GSS improvement, only atypical symptom presentation ( P = 0.021) and AET ≥ 4.0 % ( P = 0.003) represented signifi cant predictors ( Figure 2 ).
Testing on PPI
Th e 69 subjects who underwent testing on anti-secretory therapy were further analyzed. On univariate analysis assessing predic- Reported symptoms and frequency of acid refl ux events were signifi cantly higher when testing was performed off proton pump inhibitor (PPI) therapy ( * P ≤ 0.04). Frequency of refl ux events detected by impedance (all refl ux events) was similar whether testing was performed on or off PPI therapy ( P = 0.26). Both symptom index (SI) and symptom association probability (SAP) were proportionately more frequent with impedance-detected refl ux events ( * * P ≤ 0.002). 
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Acid Parameters on pH-Impedance Testing impedance-based non-acid-refl ux parameters in predicting response to PPI therapy. Specifi cally, our univariate and multivariate analyses demonstrate that total AET and abnormal AET ≥ 4.0 % predict symptomatic improvement with anti-secretory therapy to far greater degrees than total RET, abnormal RET ≥ 1.4 % , and total numbers of refl ux events. Impedance testing provided most gain in detecting refl ux events, consequently leading to higher proportions with symptom -refl ux correlation, a parameter that also predicted symptom outcome. Given the higher rates of detection of symptom -refl ux correlation on patients tested off anti-secretory therapy, our fi ndings support performing pH-impedance studies off PPI therapy to maximize clinical gain in predicting subjects who may benefi t from medical management. Acid parameters represent an established approach to predicting outcomes in GERD ( 27 ) . For instance, increased acid refl ux correlates with the presence of Barrett ' s esophagus, a long-term consequence of GERD in predisposed individuals; total AET correlates with the length of Barrett ' s esophagus ( 28 ) . As the numeric total AET value increases, the likelihood of a higher grade along the GERD spectrum (no esophagitis, esophagitis, uncomplicated Barrett ' s esophagus, complicated Barrett ' s esophagus) also increases ( 29 ) . Symptomatic GERD patients with abnormal acid exposure and / or symptom -refl ux association respond more favorably to PPI therapy than those with normal acid exposure and lack of symptom -refl ux correlation on pH testing ( 30 ) . Acid-refl ux parameters also predict successful outcome aft er ARS ( 31 ), whereas normal preoperative pH testing predicts suboptimal subjective outcome ( 32 ) . Th erefore, there is ample evidence supporting the utility of acid-driven parameters in predicting outcomes in the management of GERD, a concept that is at the core of our fi ndings in this study.
In contrast, impedance-driven outcome data are limited, despite the fact that symptom -refl ux correlation benefi ts from the use of pH-impedance testing. Our results concur with those in the literature in that impedance monitoring detects more refl ux events than pH monitoring. Although previous assessments suggest that the clinical value and optimal use of symptom -refl ux correlation remain unclear ( 33, 34 ) , we demonstrate that SAP from impedance testing is an independent predictor of symptomatic outcome aft er medical therapy of GERD. Despite this fi nding, only limited AET, acid exposure time; GSS, global symptomatic status; PPI, proton pump inhibitor; RET, refl ux exposure time; SAP, symptom association probability measured by Ghillebert probability estimate; SI, symptom index.
Th e strength of our conclusions is tempered by several limitations. Patients were identifi ed retrospectively, although data were collected prospectively; some did not complete symptom assessments at the time of the pH-impedance study, and others could not be contacted for assessment of treatment response. Follow-up symptom scores, especially global symptom scores, could have been aff ected by other non-refl ux processes including functional pain, which we did not evaluate. We did not have a comparator control group with only pH testing, which could have revealed diff erences between pH and pH-impedance monitoring; nor did we have a cohort treated with ARS, which could have put the response to medical therapy into perspective. We could not accurately assess PPI compliance at follow-up, nor reliably determine how many subjects had been treated with diff erent forms of adjunctive medical therapy for subgroup analyses. Our results demonstrated only a statistical trend in proportions of patients with abnormal AET off PPI compared with those tested on PPI, which refl ects the fact that many with markedly abnormal AET (in the off PPI cohort) were likely triaged to ARS and did not fulfi ll inclusion criteria.
Moreover, therapy following pH-impedance monitoring was not protocolized; instead, management was left to the ordering physicians, who may or may not have used accepted guidelines in planning therapeutic options. It is also not clear why many patients with normal pH-impedance parameters and off PPI were left on anti-secretory therapy by their treating physicians, but this refl ects real-world practice and contributes to overuse of PPIs. Finally, we had a higher proportion of atypical refl ux symptoms in this cohort, likely driven by the openaccess favoring of pH-impedance monitoring for atypical refl ux symptoms in the early years of pH-impedance testing. We believe this is the likely explanation for trends suggesting better prediction of symptom improvement with atypical symptoms rather than typical symptoms, as standard pH monitoring without impedance was being performed more commonly to document abnormal esophageal pH patterns for typical refl ux symptoms at that time frame. Nevertheless, we believe that our results refl ect a representative assessment of how pH-impedance monitoring studies are used in the real world, and despite these limitations, our results can help provide a starting point for planning patient management, and especially for planning future studies.
In summary, acid-based refl ux parameters have clinical utility in predicting a symptomatic response to anti-secretory therapy, whereas impedance parameters can complement acid monitoring in the detection of clinically relevant symptom -refl ux association. Abnormal acid-based refl ux parameters can predict symptom improvement with medical management better than impedancebased refl ux parameters. As abnormal acid-based parameters are detected more oft en off anti-secretory therapy, we conclude that pH-impedance testing off PPI therapy has both diagnostic and management implications when the medical management of refl ux disease is planned. Future studies need to utilize protocolized medical and surgical therapy to better evaluate the implications of pH-impedance testing.
outcome data exist to suggest a relationship between non-acidic refl ux detected by impedance testing and symptoms in suspected GERD ( 35 ) . Th e clinical signifi cance of these refl ux events must be carefully evaluated in the appropriate context ( 36 ) . Although the pH portion of the pH-impedance study and symptom -refl ux correlation can provide direction regarding signifi cance of impedance-detected refl ux events, this can only be augmented by performing the study off PPI therapy. Further, it is unclear as to how to evaluate pH fi ndings in patients on PPI therapy, unless values are clearly abnormal. Varying thresholds have been utilized to designate abnormality, but the clinical outcome from use of these thresholds remains unclear ( 14, 27, 37 ) . Th e higher rates of symptom -refl ux correlation detected by impedance testing could also be subject to overinterpretation, especially in the setting of lower frequencies of refl ux events ( 38 ) . Taking all these factors and our fi ndings into consideration, impedance monitoring has the potential to complement pH-detected refl ux events and participate in predicting outcome. However, recognition of both pH-and impedance-detected refl ux events, and, particularly, reporting of symptom events, requires testing to be performed off therapy ( 39 ) .
In this study, we evaluated the value of a cumulative bolus contact time metric to correspond to the AET, measured at the same level 5 cm proximal to the lower esophageal sphincter, which we have termed the refl ux-exposure time, or RET. Th is metric has been evaluated in normal volunteers, with normal thresholds determined ( 23 ) . It is well known that refl ux durations measured by impedance are shorter than corresponding pH-determined refl ux durations, because mucosal acidifi cation persists despite clearance of the refl uxate ( 23, 40 ) . Th erefore, impedance-detected refl ux events are brief, and symptom correlation with these brief events could be more specifi c in symptom -refl ux association testing. Further, refl uxates could generate symptoms by mechanical stretch and not just chemical stimulation, which may not trigger correlation with a pH-detected refl ux event. Hence, impedancedriven symptom -refl ux testing holds potential for added clinical value. Our data suggest that there is benefi t in symptom -refl ux association testing when pH data is supplemented with impedance data, indicating that pH-impedance monitoring clearly has a clinical role in refl ux testing.
However, acid parameters drive management, as acid suppression remains the cornerstone of GERD therapy ( 41, 42 ) . Despite the fact that refl ux of gastric contents continues despite acid suppression, most patients have adequate symptom relief from medical management with acid suppressants. Th erefore, acid parameters intuitively drive symptom outcome from medical management, and it follows that the predictive value of testing subjects off antisecretory therapy would be higher compared with those on therapy, as the diagnostic yield is much higher off therapy. In recent years, baclofen, a gamma amino butyric acid B receptor agonist, has been implemented as an adjunct to reduce the frequency of refl ux events to complement anti-secretory therapy ( 43 -45 ) . Th is agent could potentially augment medical management of refl ux and improve symptomatic outcomes by reducing refl ux events; however, baclofen was not utilized for medical management in our study cohort.
